This article is more than 5 years old. Information may no longer be current.
AMA grants CPT code for KidneyIntelX
Click Here to Manage Email Alerts
Renalytix AI plc has been granted a CPT Proprietary Laboratory Analyses Code for KidneyIntelX by the AMA.
“This is an important step as we prepare for KidneyIntelX’s scaled roll-out in the United States,” Michael J. Donovan, PhD, MD, chief medical officer of Renalytix AI, said in a press release. “A CPT code is instrumental in obtaining insurance coverage and reimbursement, and will increase access to KidneyIntelX testing results for patients with chronic kidney disease.”
KidneyIntelX is designed to improve identification and clinical management of patients with type 2 diabetes with fast-progressing kidney disease. It utilizes machine-learning algorithms to evaluate a combination of predictive blood-based biomarkers and features from a patient's electronic health record.
The payment rate for the new code will be established for Medicare patients through the 2019 Clinical Lab Fee Schedule (CLFS) annual public meeting process. The AMA CPT editorial panel approved and published the new code, 0105U, and it is scheduled to become effective on Oct. 1, 2019.
Reference:
https://renalytixai.com/us-cpt-code-granted-for-kidneyintelx/